These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 17451962)

  • 1. Structure-based design, synthesis and preliminary evaluation of selective inhibitors of dihydrofolate reductase from Mycobacterium tuberculosis.
    El-Hamamsy MH; Smith AW; Thompson AS; Threadgill MD
    Bioorg Med Chem; 2007 Jul; 15(13):4552-76. PubMed ID: 17451962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three-dimensional structure of M. tuberculosis dihydrofolate reductase reveals opportunities for the design of novel tuberculosis drugs.
    Li R; Sirawaraporn R; Chitnumsub P; Sirawaraporn W; Wooden J; Athappilly F; Turley S; Hol WG
    J Mol Biol; 2000 Jan; 295(2):307-23. PubMed ID: 10623528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New 2,4-diamino-5-(2',5'-substituted benzyl)pyrimidines as potential drugs against opportunistic infections of AIDS and other immune disorders. Synthesis and species-dependent antifolate activity.
    Rosowsky A; Forsch RA; Sibley CH; Inderlied CB; Queener SF
    J Med Chem; 2004 Mar; 47(6):1475-86. PubMed ID: 14998335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fragment Discovery for the Design of Nitrogen Heterocycles as Mycobacterium tuberculosis Dihydrofolate Reductase Inhibitors.
    Shelke RU; Degani MS; Raju A; Ray MK; Rajan MG
    Arch Pharm (Weinheim); 2016 Aug; 349(8):602-13. PubMed ID: 27320965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Saccharomyces cerevisiae screen identifies WR99210 analogues that inhibit Mycobacterium tuberculosis dihydrofolate reductase.
    Gerum AB; Ulmer JE; Jacobus DP; Jensen NP; Sherman DR; Sibley CH
    Antimicrob Agents Chemother; 2002 Nov; 46(11):3362-9. PubMed ID: 12384337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation, biological evaluation and molecular docking study of imidazolyl dihydropyrimidines as potential Mycobacterium tuberculosis dihydrofolate reductase inhibitors.
    Desai NC; Trivedi AR; Khedkar VM
    Bioorg Med Chem Lett; 2016 Aug; 26(16):4030-5. PubMed ID: 27397497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Further studies on 2,4-diamino-5-(2',5'-disubstituted benzyl)pyrimidines as potent and selective inhibitors of dihydrofolate reductases from three major opportunistic pathogens of AIDS.
    Rosowsky A; Forsch RA; Queener SF
    J Med Chem; 2003 Apr; 46(9):1726-36. PubMed ID: 12699390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective Pneumocystis carinii dihydrofolate reductase inhibitors: design, synthesis, and biological evaluation of new 2,4-diamino-5-substituted-furo[2,3-d]pyrimidines.
    Gangjee A; Guo X; Queener SF; Cody V; Galitsky N; Luft JR; Pangborn W
    J Med Chem; 1998 Apr; 41(8):1263-71. PubMed ID: 9548816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rational drug design, synthesis and biological evaluation of dihydrofolate reductase inhibitors as antituberculosis agents.
    Tawari NR; Bag S; Raju A; Lele AC; Bairwa R; Ray MK; Rajan MG; Nawale LU; Sarkar D; Degani MS
    Future Med Chem; 2015; 7(8):979-88. PubMed ID: 26062396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The identification of novel Mycobacterium tuberculosis DHFR inhibitors and the investigation of their binding preferences by using molecular modelling.
    Hong W; Wang Y; Chang Z; Yang Y; Pu J; Sun T; Kaur S; Sacchettini JC; Jung H; Lin Wong W; Fah Yap L; Fong Ngeow Y; Paterson IC; Wang H
    Sci Rep; 2015 Oct; 5():15328. PubMed ID: 26471125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of novel selective Mtb-DHFR inhibitors as antitubercular agents through structure-based computational techniques.
    Sharma K; Neshat N; Sharma S; Giri N; Srivastava A; Almalki F; Saifullah K; Alam MM; Shaquiquzzaman M; Akhter M
    Arch Pharm (Weinheim); 2020 Feb; 353(2):e1900287. PubMed ID: 31867798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis of N-{4-[(2,4-diamino-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid and N-{4-[(2-amino-4-oxo-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid as dual inhibitors of dihydrofolate reductase and thymidylate synthase and as potential antitumor agents.
    Gangjee A; Lin X; Kisliuk RL; McGuire JJ
    J Med Chem; 2005 Nov; 48(23):7215-22. PubMed ID: 16279780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and biological evaluation of 2,4-diamino-5-methyl-6-substituted-pyrrolo[2,3-d]pyrimidines as dihydrofolate reductase inhibitors.
    Gangjee A; Lin X; Queener SF
    J Med Chem; 2004 Jul; 47(14):3689-92. PubMed ID: 15214795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interactions of 5-deazapteridine derivatives with Mycobacterium tuberculosis and with human dihydrofolate reductases.
    da Cunha EF; de Castro Ramalho T; Bicca de Alencastro R; Maia ER
    J Biomol Struct Dyn; 2004 Oct; 22(2):119-30. PubMed ID: 15317473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virtual screening against Mycobacterium tuberculosis dihydrofolate reductase: suggested workflow for compound prioritization using structure interaction fingerprints.
    Kumar A; Siddiqi MI
    J Mol Graph Model; 2008 Nov; 27(4):476-88. PubMed ID: 18829358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mycobacterium tuberculosis dihydrofolate reductase is a target for isoniazid.
    Argyrou A; Vetting MW; Aladegbami B; Blanchard JS
    Nat Struct Mol Biol; 2006 May; 13(5):408-13. PubMed ID: 16648861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis of 2,4-diamino-6-[2'-O-(omega-carboxyalkyl)oxydibenz[b,f]azepin-5-yl]methylpteridines as potent and selective inhibitors of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductase.
    Rosowsky A; Fu H; Chan DC; Queener SF
    J Med Chem; 2004 May; 47(10):2475-85. PubMed ID: 15115391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel inhibitor of indole-3-glycerol phosphate synthase with activity against multidrug-resistant Mycobacterium tuberculosis.
    Shen H; Wang F; Zhang Y; Huang Q; Xu S; Hu H; Yue J; Wang H
    FEBS J; 2009 Jan; 276(1):144-54. PubMed ID: 19032598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conformationally restricted analogues of trimethoprim: 2,6-diamino-8-substituted purines as potential dihydrofolate reductase inhibitors from Pneumocystis carinii and Toxoplasma gondii.
    Gangjee A; Vasudevan A; Queener SF
    J Med Chem; 1997 Sep; 40(19):3032-9. PubMed ID: 9301665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and in vitro antifolate activity of rotationally restricted aminopterin and methotrexate analogues.
    Rosowsky A; Forsch RA; Wright JE
    J Med Chem; 2004 Dec; 47(27):6958-63. PubMed ID: 15615544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.